文献速递肝病消化道肿瘤与早癌

精准肝细胞癌筛查的风险分层与早期检测生物标志物

Risk stratification and early detection biomarkers for precision HCC screening.
PubMed 文献 · Hepatology · 2022-10-11

肝细胞癌死亡率高主要因晚期诊断。专业学会推荐慢性肝病高危人群每半年筛查,但病因从病毒转向代谢性肝病使目标人群扩大而年发病率降低,传统筛查可能不实用且不具成本效益。本综述概述临床、分子和影像学工具的新进展,讨论其临床转化框架,以期将「一刀切」筛查转变为个体化精准早检。

要点

  • 肝细胞癌筛查包括定义合理高危人群并定期重复早检。
  • 病因向代谢性肝病转变使筛查目标人群扩大而年发病率降低。
  • 现有筛查试验性能欠佳,亟需新模态和策略提高早期检出。

核心结论

  • 近期临床、分子和影像学工具的进展有望将当前「一刀切」肝细胞癌筛查转变为个体化精准早检方法,最终改善预后。

研究设计与样本

  • 综述,概述临床、分子和影像学工具的最新进展并讨论其临床转化与实施的概念框架和方法。

主要发现

  • 肝细胞癌死亡率仍高,主要因早期检测失败导致晚期诊断。
  • 专业学会推荐慢性肝病高危患者每半年筛查以提高治愈性治疗机会和生存。
  • 病因从病毒向代谢性肝病动态转变使筛查目标人群显著增加而年发病率大幅降低。
  • 当代病因下传统筛查方法可能不实用且不具成本效益。
  • 现有肝细胞癌筛查试验性能欠佳,亟需新模态和策略改善早期检测。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatocellular carcinoma (HCC) mortality remains high primarily due to late diagnosis as a consequence of failed early detection. Professional societies recommend semi-annual HCC screening in at-risk patients with chronic liver disease to increase the likelihood of curative treatment receipt and improve survival. However, recent dynamic shift of HCC etiologies from viral to metabolic liver diseases has significantly increased the potential target population for the screening, whereas annual incidence rate has become substantially lower. Thus, with the contemporary HCC etiologies, the traditional screening approach might not be practical and cost-effective. HCC screening consists of (i) definition of rational at-risk population, and subsequent (ii) repeated application of early detection tests to the population at regular intervals. The suboptimal performance of the currently available HCC screening tests highlights an urgent need for new modalities and strategies to improve early HCC detection. In this review, we overview recent developments of clinical, molecular, and imaging-based tools to address the current challenge, and discuss conceptual framework and approaches of their clinical translation and implementation. These encouraging progresses are expected to transform the current "one-size-fits-all" HCC screening into individualized precision approaches to early HCC detection and ultimately improve the poor HCC prognosis in the foreseeable future.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lee YT, Fujiwara N, Yang JD, et al. Risk stratification and early detection biomarkers for precision HCC screening. Hepatology. 2022. PMID: 36082510. doi:10.1002/hep.32779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。